Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD

World Journal of Biological Psychiatry

Volumn 11, Issue 5, 2010, Pages 709-718

  Rösler, Michael ^a   Retz, Wolfgang ^a   Fischer, Roland ^b   Ose, Claudia ^c   Alm, Barbara ^d   Deckert, Jürgen ^e   Philipsen, Alexandra ^f   Herpertz, Sabine ^g   Ammer, Richard ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b Medice Arzneimittel Putter GmbH and Co KG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^e Department of Psychiatry and Psychotherapy University of W Ü Rzburg   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Adult ADHD; Clinical trial; Emotional symptomsLong term effects; Methylphenidate

Indexed keywords

METHYLPHENIDATE; PLACEBO; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ADULT; ANGER; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; EMOTION; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; PARANOIA; PHOBIA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF CONCEPT; SELF REPORT; SYMPTOM; TREATMENT DURATION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FOLLOW UP; LONG TERM CARE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY ASSESSMENT; PSYCHOLOGY; PSYCHOMETRY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EMOTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONG-TERM CARE; MALE; METHYLPHENIDATE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY ASSESSMENT; PSYCHOMETRICS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954368129     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622971003624197     Document Type: Article

References (45)

1. Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. 2005. Long-term, open-label, study of the safety and effi cacy of ato-moxetine in adults with attention-defi cit/hyperactivity disorder: An interim analysis. J Clin Psychiatry 66:294-299.
2. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, et al. 2009. Once-daily atomoxetine for adult attention-defi cit/hyperactivity disorder. J Clin Psychopharmacology 29:44-50.
3. Banaschewski T, Coghill D, Santosh P, Zaddas A, Asherson P, Buitelaar J, et al. 2006. Long-acting medications for the hyper-kinetic disorders. Eur Child Adolesc Psychiatry 15:476-495.
4. Biederman J. 2004. Impact of comorbidity in adults with attention-defi cit/hyperactivity disorder. J Clin Psychiatry 65 (Suppl 3):3-7.
5. Biederman J, Mick E, Faraone S. 2000. Age-dependent decline of symptoms of attention-defi cit hyperactivity disorder: Impact of remission defi nition and symptom type. Am J Psychiatry 157:816-818.
6. Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ. 2005. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrum 10:16-25. (Pubitemid 43010494)
7. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. 2006. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 59:829-835.
8. Brotman MA, Schmajuk M, Rich BA, Dickstein DJ, Guyer AE, Costello EJ, et al. 2006. Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biol Psychiatry 60:991-997.
9. Brown TE. 1996. Brown Attention-Defi cit Disorder Scales for Adolescents and Adults. London: Psychological Corporation.
10. Conners CK, Erhardt D, Sparrow E. 1999. CAARS-Adult ADHD Rating Scales-Technical Manual. New York: MHS.
11. Derogatis LR. 1977. SCL-90-R, administration, scoring&procedures. Manual for the revised version. Baltimore, MD: Johns Hopkins University.
12. DuPaul G, Power T, Anastopoulos A, Reid R. 1998. ADHD Rating Scale-IV: Checklist, norms, and clinical interpretation. New York: Guilford.
13. Fayyad J, De Graf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. 2007. Cross-national prevalence and correlates of adult attention-defi cit hyperactivity disorder. Br J Psychiatry 190:402-409.
14. Faraone S V. 2005. The scientifi c foundation for understanding attention-defi cit/hyperactivity disorder as a valid psychiatric disorder. Eur Child Adolesc Psychiatry 14:1-10.
15. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. 2004. Meta-analysis of the effi cacy of methylphenidate for treating adult attention-defi cit/hyperactivity disorder. J Clin Psychop-harmacol 24:24-29.
16. Gibbins C, Weiss M. 2007. Clinical recommendations in current practice guidelines in diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep 9:420-426.
17. Jain U, Hechtman L, Weiss M, Ahmed TS, Reiz J, Donnelly GAE, et al. 2007. Effi cacy of a novel biphasic controlled-release methylphenidate formula in adults with attention defi cit hyper-activity disorder: Results of a double-blind placebo-controlled crossover study. J Clin Psychiatry 68:268-277.
18. Koesters M, Becker T, Kilian R, Fegert JM, Weinmann S. 2009. Limits of meta-analysis: methylphenidate in the treatment of adult attention-defi cit hyperactivity disorder. J Psychopharmacol 23:733-744.
19. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. 1993. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 50:565-576.
20. McGough JJ, Barkley RA. 2004. Diagnostic controversies in adult attention defi cit hyperactivity disorder. Am J Psychiatry 161:1948-1956.
21. McGough JJ, McCracken JT. 2006. Adult attention defi cit hyper-activity disorder: Moving beyond DSM-IV. Am J Psychiatry 163:1673-1675.
22. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. 2003. Atomoxetine in adults with ADHD. Two randomized. placebo-controlled studies. Biol Psychiatry 15:112-120.
23. Moll GH, Eysenbach K, Woerner W, Banaschewski T, Schmidt MH, Rothenberger A. 2000. Quantitative and qualitative aspects of obsessive-compulsive behavior in children with attention-defi cit hyperactivity disorder compared with tic disorder. Acta Psy-chiatr Scand 101:389-394
24. NICE. 2008. Attention defi cit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. epub 3 November 2008 [www.nice.org.uk].
25. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. 2007. Evidence-based guidelines for management of attention-defi cit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21:10-41.
26. Philipsen A, Limberger MF, Lieb K, Feige B, Kleindienst N, Ebner-Priemer U, et al. 2008. Attention-defi cit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry 192:118-123.
27. Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, et al. 2005. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 58: 125-131.
28. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Merchant BK. 2007. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93-101.
29. Retz-Junginger P, Retz W, Blocher D, Weijers T, Wender PH, Rösler M. 2002. (Wender Utah Rating Scale. The short-version for the assessment of the attention-defi cit hyperactivity disorder in adults). Nervenarzt 73:830-838.
30. Retz-Junginger P, Retz W, Blocher D, Stieglitz RD, Supprian T, Wender PH, Rösler M. 2003. (Reliability and validity of the German short version of the Wender-Utah Rating Scale for the retrospective assessment of attention defi cit/hyperactivity disorder). Nervenarzt 74:987-993.
31. Rösler M, Retz W, Retz-Junginger P, Thome J, Supprian T, Nissen T, et al. 2004. (Tools for the diagnosis of attention-defi cit/hyperactivity disorder in adults. Self-rating behaviour questionnaire and diagnostic checklist) Nervenarzt 75: 888-895.
32. Rösler M, Retz W, Thome J, Schneider M, Stieglitz R-D, Falkai P. 2006. Psychopathological rating scales for diagnostic use in adults with attention defi cit/hyperactivity disorder (ADHD) Eur Arch Psychiatry Clin Neurosci 256 (Suppl 1):3-11.
33. Rösler M, Retz-Junginger P, Retz W, Stieglitz R-D. 2008a. HASE-Homburger ADHS Skalen für Erwachsene. Göttingen: Hogrefe.
34. Rösler M, Retz W, Retz-Junginger P, Stieglitz R-D, Kessler H, Reimherr F, Wender PH. 2008b. (Attention defi cit hyperactivity disorder in adults. Benchmarking diagnosis using the Wender-Reimherr adult ADHD rating scale). Nervenarzt 79:320-327.
35. Rösler M, Fischer R, Ammer R, Ose C, Retz W. 2009. A randomized, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-defi cit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120-129.
36. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffi n S. 1996. Pharmacotherapy of attention deficit hyperactivity disorder across the lifecycle: A literature review. J Am Acad Child Adolesc Psychiatry 35:409-432.
37. Spencer T, Biederman J, Wilens TE, Faraone S, Prince J, Gerard K, et al. 2001. Effi cacy of a mixed amphetamine salts compound in adults with attention-defi cit/hyperactivity disorder. Arch Gen Psychiatry 58:775-782.
38. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. 2005. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 57:456-463.
39. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L. 2007. Effi cacy and safety of dexmeythlphenidate extended-release capsules in adults with attention-defi cit/hyperactivity disorder. Biol Psychiatry 61:1380-1387.
40. Walcott CM, Landau S. 2004. The relation between disinhibi-tion and emotional regulation in boys with attention-defi cit/hyperactivity disorder. J Clin Child Adolesc Psychol 33: 772-782.
41. Weiss G, Hechtman LT, Milroy T, Perlman T. 1985. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 24:211-220.
42. Weiss MD, Weiss JR. 2004. A guide to the treatment of adults with ADHD. J Clin Psychiatry 65 (Suppl 3):27-37.
43. Wender PH. 1995. Attention-defi cit hyperactivity disorder in adults. Oxford, New York: Oxford University Press.
44. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M. 1997. Strukturiertes Klinisches Interview für DSM-IV (SKID). Göttingen: Hogrefe.
45. Woo BS, Rey JM. 2005. The validity of the DSM-IV subtypes of attention-defi cit/hyperactivity disorder. Aust NZ J Psychiatry 39:344-353.